Inhibitex to Present at the 2011 Canaccord Genuity Growth Conference on Tuesday, August 9th
August 04 2011 - 4:20PM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H.
Plumb, president and chief executive officer, will present an
overview of the company and its pipeline of differentiated
antiviral compounds at the Canaccord Genuity Growth Conference on
Tuesday, August 9, 2011 at 3:30 p.m. EDT. The conference is being
held at The Intercontinental Hotel in Boston, Massachusetts. The
presentation will be simultaneously webcast and can be accessed by
visiting the Investors section of the Inhibitex website
at www.inhibitex.com. Shortly following the live webcast a
replay will also be available on the Company website.
About Inhibitex
Inhibitex, Inc. is a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s clinical-stage pipeline currently includes
two Phase 2 development programs; INX-189, a nucleotide polymerase
inhibitor in development for the treatment of chronic hepatitis C
infections and FV-100, a nucleoside analogue in development for the
treatment of shingles-associated pain. The Company also has
additional HCV nucleotide polymerase inhibitors in preclinical
development and has licensed the use of its proprietary MSCRAMM®
protein platform to Pfizer for the development of a staphylococcal
vaccine, which is currently being evaluated in a Phase 1 clinical
trial. For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024